Program News
News and stories about the UNC Lineberger Pancreatic Cancer Center of Excellence
-
Pancreatic Cancer SPORE Developmental Awards: Highlights From the First Two Years
The Selective Targeting of Pancreatic Cancer (SToP) Specialized Program of Research Excellence (SPORE) grant has teamed up with UNC Lineberger’s Developmental Research Program (DRP) to support novel projects seeking to gain key insight into critical areas of pancreatic cancer research.
-
New drug combinations found to potentially be more effective in targeting pancreatic cancers
UNC Lineberger researchers and colleagues have discovered an important overlap in genes regulated by the activity of three proteins that support the growth of pancreatic cancer.
-
Study now recruiting patients to treat PANcreatic adenocarcinoma with Gemcitabine, Erlotinib, and nAb-paclitaxel (PANGEA)
UNC Lineberger has opened a two-arm clinical trial to determine the optimal combination treatment for patients with advanced unresectable or metastatic basal-like subtype pancreatic ductal adenocarcinoma.
-
UNC Lineberger hosts NCI in gastrointestinal cancer SPORE Investigators Meeting
The nation’s top gastrointestinal cancer clinical translational researchers convened in Chapel Hill for the 2025 GI SPORE Investigators Meeting.
-
Peng, Xu published in Cancer Discovery
Researchers in the lab of Jen Jen Yeh, MD, have identified two kinotypes that differentiate the two established molecular subtypes pancreatic cancer, as reported in a paper published in Cancer Discovery.
-
Twins team up on cancer research
Ryan and Brandon Mouery have always been together, including now at UNC Lineberger where they study ways to improve pancreatic cancer treatments.
-
Q&A with the Care Team: Get to Know our Nurse Practitioners and Navigators
Nurse navigators and nurse practitioners are crucial members of our team at the N.C. Basnight Cancer Hospital, UNC Lineberger’s clinical home.
-
Milner awarded $2.79 million NIH grant to study epigenetic regulation of T cell exhaustion
The NIH has awarded a five-year, $2.79 million R01 research grant to Justin Milner, PhD, to define how a druggable family of epigenetic regulators control T cell activity.